retatrutide clinical trial phase retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Phase III retatrutide study demonstrates

Carraro-Lacroix, L

Increasing access will require addressing the significant barriers to care, such as treatment cost, site of care, and the policies that insurance plans can implement, such as step therapy and prior authorizations. For the study, the team used national insurance claims data for more than 97,000 commercially insured US adults diagnosed with obesity, but not diabetes, between June 2021 and July 2022

This is a game-changer

Who Responds Best to Retatrutide

The glucagon receptor agonism in retatrutide is thought to be the key driver here glucagon promotes hepatic lipid oxidation, essentially helping the liver burn its own fat stores

But the Phase 3 TRIUMPH-4 trial, which ran for 68 weeks, showed an average reduction of 28.7% at the same 12 mg dose